Investigations on biomarker search in patients with bronchial carcinoma under antibody (checkpoint blockade) therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022872

Enrollment

Registered

2020-11-02

Start date

2020-01-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C34.9

Interventions

Group 1: Determination of the immune cell repertoire in the peripheral blood of patients with SCLC at different times of immunochemotherapy (1st and 3rd cycle) using flow cytometry

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Patients must be able to give consent themselves - signed consent form - histologically confirmed SCLC with indication for palliative immunochemotherapy

Exclusion criteria

Exclusion criteria: - histologically confirmed NSCLC - previous immunotherapies

Design outcomes

Primary

Measure	Time frame
progression-free survival - Determination by CT scans after 4th cycle and then every 3 months	—

Secondary

Measure	Time frame
Overall survival - Provision for regular inquiries to the family doctor or the clinical cancer register	—

Countries

Germany

Contacts

Public ContactWolfgang Schütte

Krankenhaus Martha-Maria Halle-Dölau

Innere-Medizin2.Halle@Martha-Maria.de0345-559 1440

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026